argenx Buys Unnatural Products for $1.15 Billion
The Santa Cruz biotech's oral macrocyclic peptide platform will join argenx's discovery operations under a deal expected to close by year-end 2026.
Updated on Nov. 9, 2026 in Biotech
Live Poll
Do you trust large drug companies to deliver better medicines when they buy smaller firms?
argenx agreed to acquire Unnatural Products, Inc. (UNP) for up to $1.15 billion, including a $550 million upfront payment and contingent value rights tied to development and regulatory milestones. argenx expects the acquisition to close by year-end 2026, subject to customary closing conditions.
Why it matters
The deal adds macrocyclic peptide capabilities to argenx's antibody engineering work, with argenx stating UNP brings tools for oral and long-acting medicines. For Santa Cruz, it keeps a biotech employing more than 50 people in the city as a dedicated discovery hub after closing.
UNP's platform pairs AI-guided design with massively parallel synthesis and direct-to-biology screening, developed over roughly 10 years. The contingent value rights depend on development and regulatory milestones whose timing and thresholds were not disclosed in the announcement.
The players
argenx
argenx is a Dutch biopharmaceutical company known for its antibody engineering work and its development of efgartigimod.
Unnatural Products, Inc.
Unnatural Products, Inc. is a Santa Cruz biotech focused on orally-delivered macrocyclic peptides and AI-guided molecular design.
The details
argenx will acquire all outstanding equity of UNP, a biotech developing orally-delivered macrocyclic peptides founded in 2016 by Cameron Pye and Joshua Schwochert. UNP will keep operating from its Santa Cruz, California site after closing and has partnerships with Novartis, Merck, and BridgeBio.
Timeline
2016: UNP is founded in Santa Cruz by Cameron Pye and Joshua Schwochert.
Past two years: argenx and UNP collaborate on a multi-target research program.
November 9, 2026: The definitive acquisition agreement is announced.
Year-end 2026: The acquisition is expected to close.
Roadmap
Oral macrocyclic peptides aim to deliver drug classes that have traditionally required injections, a goal pursued across the biotech sector. argenx's purchase of UNP extends that effort from antibody engineering into a modality designed for pill-form delivery.
For patients, the deal points toward future medicines that could be taken as pills rather than injections, though no products are named in the announcement. Residents of Santa Cruz may see the biotech's workforce remain local as UNP keeps operating from its existing site.
The takeaway
The deal shows large drugmakers are paying for platforms that could turn injectable drug classes into oral medicines. Its final value depends on milestones that have not yet been met.
What happens next
argenx expects the acquisition to close by year-end 2026, subject to customary closing conditions.
Further reading
For more on the sector behind the deal, see Biotech coverage.
More information
Visit the Unnatural Products company website for more on its macrocyclic peptide platform.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you trust large drug companies to deliver better medicines when they buy smaller firms?
